Laboratorios Farmaceúticos Rovi SA (LABFF)
67.17
0.00 (0.00%)
USD |
OTCM |
Aug 26, 16:00
Laboratorios Farmaceúticos Rovi Net Income (Quarterly) : 87.12M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 87.12M |
| March 31, 2026 | 11.05M |
| December 31, 2025 | 49.65M |
| September 30, 2025 | 67.79M |
| June 30, 2025 | 24.51M |
| March 31, 2025 | 19.02M |
| December 31, 2024 | 24.95M |
| September 30, 2024 | 75.96M |
| June 30, 2024 | 31.63M |
| March 31, 2024 | 16.24M |
| December 31, 2023 | 55.36M |
| September 30, 2023 | 56.76M |
| June 30, 2023 | 20.88M |
| March 31, 2023 | 50.92M |
| December 31, 2022 | 79.74M |
| September 30, 2022 | 41.19M |
| June 30, 2022 | 29.30M |
| March 31, 2022 | 59.51M |
| December 31, 2021 | 61.88M |
| September 30, 2021 | 56.48M |
| June 30, 2021 | 32.78M |
| March 31, 2021 | 28.71M |
| December 31, 2020 | 16.97M |
| September 30, 2020 | 20.14M |
| June 30, 2020 | 17.26M |
| Date | Value |
|---|---|
| March 31, 2020 | 15.33M |
| December 31, 2019 | 9.512M |
| September 30, 2019 | 16.14M |
| June 30, 2019 | 10.41M |
| March 31, 2019 | 7.831M |
| December 31, 2018 | 2.561M |
| September 30, 2018 | 9.422M |
| June 30, 2018 | 0.8479M |
| March 31, 2018 | 8.404M |
| December 31, 2017 | 0.2602M |
| September 30, 2017 | 1.484M |
| June 30, 2017 | 10.33M |
| March 31, 2017 | 6.794M |
| December 31, 2016 | 4.929M |
| September 30, 2016 | 3.919M |
| June 30, 2016 | 9.708M |
| March 31, 2016 | 10.37M |
| December 31, 2015 | 3.611M |
| September 30, 2015 | 3.268M |
| June 30, 2015 | 7.875M |
| March 31, 2015 | 7.252M |
| December 31, 2014 | 5.313M |
| September 30, 2014 | 6.502M |
| June 30, 2014 | 12.38M |
| March 31, 2014 | 8.125M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Almirall SA | 28.25M |
| AstraZeneca PLC | 3.076B |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 222.85M |
| Total Expenses (Quarterly) | 135.65M |
| EPS Diluted (Quarterly) | 1.705 |
| Enterprise Value | 3.431B |
| Gross Profit Margin (Quarterly) | 63.56% |
| Profit Margin (Quarterly) | 39.09% |
| Earnings Yield | 6.28% |
| Operating Earnings Yield | 5.12% |
| Normalized Earnings Yield | 6.278 |